Advertisement

Increased dopamine transporter density in Parkinson's disease patients with social anxiety disorder

  • Tais S. Moriyama
    Correspondence
    Corresponding author at: Instituto Israelita de Ensino e Pesquisa Albert Einstein, Hospital Albert Einstein, Francisco Morato Av., 4293, Postal Code 05521-000, São Paulo, Brazil. Tel.: +55 11 82739898; fax: +55 11 55396137.
    Affiliations
    Instituto do Cérebro, Instituto de Ensino e Pesquisa do Hospital Israelita Albert Einstein, Sao Paulo, Brazil

    LiNC, Laboratório Interdisciplinar de Neurociências Clínicas do Departamento de Psiquiatria da Universidade Federal de São Paulo, UNIFESP, São Paulo, Brazil
    Search for articles by this author
  • André C. Felicio
    Affiliations
    Instituto do Cérebro, Instituto de Ensino e Pesquisa do Hospital Israelita Albert Einstein, Sao Paulo, Brazil

    LiNC, Laboratório Interdisciplinar de Neurociências Clínicas do Departamento de Psiquiatria da Universidade Federal de São Paulo, UNIFESP, São Paulo, Brazil

    Departamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo, São Paulo, Brazil
    Search for articles by this author
  • Marcos H.N. Chagas
    Affiliations
    Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil

    INCT Translational Medicine, CNPq, Brazil
    Search for articles by this author
  • Vítor S. Tardelli
    Affiliations
    LiNC, Laboratório Interdisciplinar de Neurociências Clínicas do Departamento de Psiquiatria da Universidade Federal de São Paulo, UNIFESP, São Paulo, Brazil
    Search for articles by this author
  • Henrique Ballalai Ferraz
    Affiliations
    Departamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo, São Paulo, Brazil
    Search for articles by this author
  • Vitor Tumas
    Affiliations
    Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil

    INCT Translational Medicine, CNPq, Brazil
    Search for articles by this author
  • Edson Amaro-Junior
    Affiliations
    Instituto do Cérebro, Instituto de Ensino e Pesquisa do Hospital Israelita Albert Einstein, Sao Paulo, Brazil
    Search for articles by this author
  • Luiz Augusto F. Andrade
    Affiliations
    Instituto do Cérebro, Instituto de Ensino e Pesquisa do Hospital Israelita Albert Einstein, Sao Paulo, Brazil
    Search for articles by this author
  • Jose Alexandre Crippa
    Affiliations
    Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil

    INCT Translational Medicine, CNPq, Brazil
    Search for articles by this author
  • Rodrigo A. Bressan
    Affiliations
    Instituto do Cérebro, Instituto de Ensino e Pesquisa do Hospital Israelita Albert Einstein, Sao Paulo, Brazil

    LiNC, Laboratório Interdisciplinar de Neurociências Clínicas do Departamento de Psiquiatria da Universidade Federal de São Paulo, UNIFESP, São Paulo, Brazil
    Search for articles by this author

      Abstract

      Social Anxiety Disorder (SAD) is more common among PD patients than in the general population. This association may be explained by psychosocial mechanisms but it is also possible that neurobiological mechanism underlying PD can predispose to SAD. The aim of this study was to investigate a possible dopaminergic mechanism involved in PD patients with SAD, by correlating striatal dopamine transporter binding potential (DAT-BP) with intensity of social anxiety symptoms in PD patients using SPECT with TRODAT-1 as the radiopharmaceutical. Eleven PD patients with generalized SAD and 21 PD patients without SAD were included in this study; groups were matched for age, gender, disease duration and disease severity. SAD diagnosis was determined according to DSM IV criteria assessed with SCID-I and social anxiety symptom severity with the Brief Social Phobia Scale (BSPS). Demographic and clinical data were also collected. DAT-BP was significantly correlated to scores on BSPS for right putamen (r=0.37, p=0.04), left putamen (r=0.43, p=0.02) and left caudate (r=0.39, p=0.03). No significant correlation was found for the right caudate (r=0.23, p=0.21). This finding may reinforce the hypothesis that dopaminergic dysfunction might be implicated in the pathogenesis of social anxiety in PD.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Findley L.J.
        The economic impact of Parkinson's disease.
        Parkinsonism Relat Disord. Sep. 2007; ([Review]): S8-S12
      1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington, DC2000
        • Stein M.B.
        • Stein D.J.
        Social anxiety disorder.
        Lancet. Mar. 29 2008; 371: 1115-1125
        • Kessler R.C.
        The impairments caused by social phobia in the general population: implications for intervention.
        Acta Psychiatr Scand Suppl. 2003; 417: 19-27
        • Pontone G.M.
        • Williams J.R.
        • Anderson K.E.
        • Chase G.
        • Goldstein S.A.
        • Grill S.
        • et al.
        Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease.
        Mov Disord. Jul. 15 2009; 24: 1333-1338
        • de Rijk C.
        • Bijl R.V.
        Prevalence of mental disorders in persons with Parkinson's disease.
        Ned Tijdschr Geneeskd. Jan. 3 1998; 142: 27-31
        • Bolluk B.
        • Ozel-Kizil E.T.
        • Akbostanci M.C.
        • Atbasoglu E.C.
        Social anxiety in patients with Parkinson's disease.
        J Neuropsychiatry Clin Neurosci. Fall 2010; 22: 390-394
        • Stein M.B.
        • Heuser I.J.
        • Juncos J.L.
        • Uhde T.W.
        Anxiety disorders in patients with Parkinson's disease.
        Am J Psychiatry. Feb. 1990; 147: 217-220
        • Kummer A.
        • Cardoso F.
        • Teixeira A.L.
        Frequency of social phobia and psychometric properties of the Liebowitz social anxiety scale in Parkinson's disease.
        Mov Disord. Sep. 15 2008; 23: 1739-1743
        • Robinson H.M.
        • Hood S.D.
        • Bell C.J.
        • Nutt D.J.
        Dopamine and social anxiety disorder.
        Rev Bras Psiquiatr. Dec. 2006; 28: 263-264
        • Mikkelsen E.J.
        • Detlor J.
        • Cohen D.J.
        School avoidance and social phobia triggered by haloperidol in patients with Tourette's disorder.
        Am J Psychiatry. Dec. 1981; 138 ([Case Reports Research Support, U.S. Gov't, P.H.S.]): 1572-1576
        • Pallanti S.
        • Quercioli L.
        • Rossi A.
        • Pazzagli A.
        The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation.
        J Clin Psychiatry. Dec. 1999; 60 ([Case Reports Clinical Trial]): 819-823
        • Schneier F.R.
        • Liebowitz M.R.
        • Abi-Dargham A.
        • Zea-Ponce Y.
        • Lin S.H.
        • Laruelle M.
        Low dopamine D(2) receptor binding potential in social phobia.
        Am J Psychiatry. Mar. 2000; 157: 457-459
        • Schneier F.R.
        • Martinez D.
        • Abi-Dargham A.
        • Zea-Ponce Y.
        • Simpson H.B.
        • Liebowitz M.R.
        • et al.
        Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings.
        Depress Anxiety. 2008; 25: 1-7
        • Tiihonen J.
        • Kuikka J.
        • Bergstrom K.
        • Lepola U.
        • Koponen H.
        • Leinonen E.
        Dopamine reuptake site densities in patients with social phobia.
        Am J Psychiatry. Feb. 1997; 154: 239-242
        • van der Wee N.J.
        • van Veen J.F.
        • Stevens H.
        • van Vliet I.M.
        • van Rijk P.P.
        • Westenberg H.G.
        Increased serotonin and dopamine transporter binding in psychotropic medication-naive patients with generalized social anxiety disorder shown by 123I-beta-(4-iodophenyl)-tropane SPECT.
        J Nucl Med. May 2008; 49: 757-763
        • Sareen J.
        • Campbell D.W.
        • Leslie W.D.
        • Malisza K.L.
        • Stein M.B.
        • Paulus M.P.
        • et al.
        Striatal function in generalized social phobia: a functional magnetic resonance imaging study.
        Biol Psychiatry. Feb. 1 2007; 61 ([Research Support, Non-U.S. Gov't]): 396-404
        • Johnson M.R.
        • Lydiard R.B.
        • Zealberg J.J.
        • Fossey M.D.
        • Ballenger J.C.
        Plasma and CSF HVA levels in panic patients with comorbid social phobia.
        Biol Psychiatry. Sep. 15 1994; 36: 425-427
        • McGrath M.
        • Kawachi I.
        • Ascherio A.
        • Colditz G.A.
        • Hunter D.J.
        • De Vivo I.
        Association between catechol-O-methyltransferase and phobic anxiety.
        Am J Psychiatry. Sep. 2004; 161: 1703-1705
        • Blanco C.
        • Raza M.S.
        • Schneier F.R.
        • Liebowitz M.R.
        The evidence-based pharmacological treatment of social anxiety disorder.
        Int J Neuropsychopharmacol. Dec. 2003; 6 ([Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review]): 427-442
        • Shih M.C.
        • Franco de Andrade L.A.
        • Amaro Jr., E.
        • Felicio A.C.
        • Ferraz H.B.
        • Wagner J.
        • et al.
        Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?—a [99mTc]-TRODAT-1 SPECT study.
        Mov Disord. Apr. 30 2007; 22 (Research Support, Non-U.S. Gov't]): 863-866
        • Weng Y.H.
        • Yen T.C.
        • Chen M.C.
        • Kao P.F.
        • Tzen K.Y.
        • Chen R.S.
        • et al.
        Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects.
        J Nucl Med. Mar. 2004; 45 ([Clinical Trial Controlled Clinical Trial Research Support, Non-U.S. Gov't]): 393-401
        • Felicio A.C.
        • Moriyama T.S.
        • Godeiro-Junior C.
        • Shih M.C.
        • Hoexter M.Q.
        • Borges V.
        • et al.
        Higher dopamine transporter density in Parkinson's disease patients with depression.
        Psychopharmacology (Berl). Jul. 2010; 211 ([Research Support, Non-U.S. Gov't]): 27-31
        • Gibb W.R.
        • Lees A.J.
        The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
        J Neurol Neurosurg Psychiatry. 1988 Jun; 51: 745-752
        • Brucki S.M.
        • Nitrini R.
        • Caramelli P.
        • Bertolucci P.H.
        • Okamoto I.H.
        Suggestions for utilization of the mini-mental state examination in Brazil.
        Arq Neuropsiquiatr. Sep. 2003; 61: 777-781
        • Llebaria G.
        • Pagonabarraga J.
        • Kulisevsky J.
        • Garcia-Sanchez C.
        • Pascual-Sedano B.
        • Gironell A.
        • et al.
        Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease.
        Mov Disord. Aug. 15 2008; 23 ([Research Support, Non-U.S. Gov't]): 1546-1550
        • Del-Ben C.M.
        • Vilela J.A.A.
        • Crippa J.A.S.
        • Hallak J.E.C.
        • Labate C.M.
        • Zuardi A.W.
        Confiability of the structured clinical interview for DSM-IV — clinical version translated into Portuguese.
        Rev Bras Psiquiatr. 2001; 23: 156-159
        • Aarsland D.
        • Marsh L.
        • Schrag A.
        Neuropsychiatric symptoms in Parkinson's disease.
        Mov Disord. Nov. 15 2009; 24 ([Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]): 2175-2186
        • Osorio F.L.
        • Crippa J.A.
        • Loureiro S.R.
        Study of the psychometric qualities of the Brief Social Phobia Scale (BSPS) in Brazilian university students.
        Eur Psychiatry. Apr. 2010; 25 ([Comparative Study Research Support, Non-U.S. Gov't]): 178-188
        • Tumas V.
        • Ujikawa L.T.
        • Ferreira G.M.
        Utility and reliability of a simplified clinical scale for Parkinson's disease.
        Arq Neuropsiquiatr. 2004; 62: 220-221
        • Hoehn M.M.
        • Yahr M.D.
        Parkinsonism: onset, progression and mortality.
        Neurology. May 1967; 17: 427-442
        • Schwab R.S.
        • England A.C.
        Projection technique for evaluating surgery in Parkinson's disease.
        in: Gillingham F.J. Donaldson I.M.L. 1969 (Edinburgh: Livingstone)
        • Kung M.P.
        • Stevenson D.A.
        • Plossl K.
        • Meegalla S.K.
        • Beckwith A.
        • Essman W.D.
        • et al.
        [99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent.
        Eur J Nucl Med. Apr. 1997; 24 ([Comparative Study Research Support, U.S. Gov't, P.H.S.]): 372-380
        • Shih M.C.
        • Amaro Jr., E.
        • Ferraz H.B.
        • Hoexter M.Q.
        • Goulart F.O.
        • Wagner J.
        • et al.
        Neuroimaging of the dopamine transporter in Parkinsons disease: first study using [99mTc]-TRODAT-1 and SPECT in Brazil.
        Arq Neuropsiquiatr. Sep. 2006; 64: 628-634
        • Schneier F.R.
        • Abi-Dargham A.
        • Martinez D.
        • Slifstein M.
        • Hwang D.R.
        • Liebowitz M.R.
        • et al.
        Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder.
        Depress Anxiety. 2009; 26 ([Research Support, N.I.H., Extramural]): 411-418
        • Grant K.A.
        • Shively C.A.
        • Nader M.A.
        • Ehrenkaufer R.L.
        • Line S.W.
        • Morton T.E.
        • et al.
        Effect of social status on striatal dopamine D2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography.
        Synapse. May 1998; 29 ([Research Support, U.S. Gov't, P.H.S.]): 80-83
        • Martinez D.
        • Orlowska D.
        • Narendran R.
        • Slifstein M.
        • Liu F.
        • Kumar D.
        • et al.
        Dopamine type 2/3 receptor availability in the striatum and social status in human volunteers.
        Biol Psychiatry. Feb. 1 2010; 67 ([Research Support, N.I.H., Extramural]): 275-278
        • Barnett S.D.
        • Kramer M.L.
        • Casat C.D.
        • Connor K.M.
        • Davidson J.R.
        Efficacy of olanzapine in social anxiety disorder: a pilot study.
        J Psychopharmacol. Dec. 2002; 16 ([Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't]): 365-368
        • Kendler K.S.
        • Gallagher T.J.
        • Abelson J.M.
        • Kessler R.C.
        Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey.
        Arch Gen Psychiatry. Nov. 1996; 53 ([Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]): 1022-1031
        • Felicio A.C.
        • Shih M.C.
        • Godeiro-Junior C.
        • Andrade L.A.
        • Bressan R.A.
        • Ferraz H.B.
        Molecular imaging studies in Parkinson disease: reducing diagnostic uncertainty.
        Neurologist. Jan. 2009; 15 ([Research Support, Non-U.S. Gov't Review]): 6-16
        • Robinson R.G.
        • Chemerinski E.
        • Jorge R.
        Pathophysiology of secondary depressions in the elderly.
        J Geriatr Psychiatry Neurol. Fall 1999; 12 ([Research Support, U.S. Gov't, P.H.S. Review]): 128-136
        • Cardoso E.F.
        • Maia F.M.
        • Fregni F.
        • Myczkowski M.L.
        • Melo L.M.
        • Sato J.R.
        • et al.
        Depression in Parkinson's disease: convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus.
        Neuroimage. Aug. 15 2009; 47 ([Research Support, Non-U.S. Gov't]): 467-472
        • Weintraub D.
        • Newberg A.B.
        • Cary M.S.
        • Siderowf A.D.
        • Moberg P.J.
        • Kleiner-Fisman G.
        • et al.
        Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease.
        J Nucl Med. Feb. 2005; 46 ([Clinical Trial Controlled Clinical Trial Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]): 227-232
        • Richard I.H.
        • Frank S.
        • McDermott M.P.
        • Wang H.
        • Justus A.W.
        • Ladonna K.A.
        • et al.
        The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations.
        Cogn Behav Neurol. Dec. 2004; 17: 201-207
        • Menza M.A.
        • Robertson-Hoffman D.E.
        • Bonapace A.S.
        Parkinson's disease and anxiety: comorbidity with depression.
        Biol Psychiatry. Oct. 1 1993; 34: 465-470
        • Fleminger S.
        Left-sided Parkinson's disease is associated with greater anxiety and depression.
        Psychol Med. Aug. 1991; 21: 629-638
        • Sonntag H.
        • Wittchen H.U.
        • Hofler M.
        • Kessler R.C.
        • Stein M.B.
        Are social fears and DSM-IV social anxiety disorder associated with smoking and nicotine dependence in adolescents and young adults?.
        Eur Psychiatry. Feb. 2000; 15 ([Research Support, Non-U.S. Gov't]): 67-74
        • Drew A.E.
        • Werling L.L.
        Nicotinic receptor-mediated regulation of the dopamine transporter in rat prefrontocortical slices following chronic in vivo administration of nicotine.
        Schizophr Res. Dec. 1 2003; 65 ([Research Support, Non-U.S. Gov't]): 47-55
        • Sharma A.
        • Brody A.L.
        In vivo brain imaging of human exposure to nicotine and tobacco.
        Handb Exp Pharmacol. 2009; 192 ([Review]): 145-171
        • Aguiar Pde C.
        • Lessa P.S.
        • Godeiro Jr., C.
        • Barsottini O.
        • Felicio A.C.
        • Borges V.
        • et al.
        Genetic and environmental findings in early-onset Parkinson's disease Brazilian patients.
        Mov Disord. Jul. 15 2008; 23 ([Research Support, Non-U.S. Gov't]): 1228-1233
        • Sossi V.
        • de la Fuente-Fernandez R.
        • Schulzer M.
        • Troiano A.R.
        • Ruth T.J.
        • Stoessl A.J.
        Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
        Ann Neurol. Nov. 2007; 62 ([Comparative Study Research Support, Non-U.S. Gov't]): 468-474